Genetic Testing May Increase Fear of Recurrence

Sarah Montini, BSN, RN, OCN, provides an in-depth look at abemaciclib for the treatment of patients with breast cancer in a downloadable reference sheet.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Breast-conserving therapy following preoperative systemic therapy resulted in superior overall survival compared with mastectomy in patients with HER2-positive breast cancer.

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

The biologics license application for datopotamab deruxtecan has been accepted by the FDA for pretreated HR-positive, HER2-negative metastatic breast cancer.

Patients with early-stage breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor provided a greater invasive disease-free survival benefit compared with nonsteroidal aromatase inhibitor therapy alone.